Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2017

View Archived Issues

Spring Bank announces latest results from phase II inarigivir study

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Seres Therapeutics announces collaboration to test its microbiome therapies in cancer patients

OncoArendi Therapeutics patents arginase inhibitors

Bayer discovers new vasopressin receptor antagonists

FDA approves Genentech's Gazyva in new indication

GlaxoSmithKline discloses novel EZH2 inhibitors

Shanghai De Novo Pharmatech has presented TLR8 agonists

Amgen presents novel apelin receptor agonists

Sutent now approved in U.S. as adjuvant treatment for adults at high risk of recurrent RCC

Bayer and PeptiDream establish drug discovery collaboration

Evelo Biosciences and Mayo Clinic enter monoclonal microbial collaboration

Deerfield Management and Johns Hopkins announce creation of Bluefield Innovations

NICE recommends routine funding for Ibrance and Kisqali in England

Bayer presents preclinical data on the cardiac effects of BAY-1142524 after myocardial infarction

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

NIH grant supports MRSA osteomyelitis research at University of Rochester

FDA first to approve Hemlibra for hemophilia A

Thetis Pharmaceuticals obtains NIH grant to support development of ulcerative colitis drug

Bayer reports first-in-human data for BR-6819

FDA issues alert regarding Takeda's febuxostat for gout

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

FDA approves new formulation and pediatric indication for Tekturna

PIN Pharma begins phase I study of immune-modulator in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.